In our study, we focused on the expression of CD9 in myeloproliferative neoplasms—specifically those linked to the JAK2 (V617F) mutation, such as polycythemia vera, and essential thrombocythemia. The gene discussed is CD9; the disease is myeloproliferative neoplasm.